133 related articles for article (PubMed ID: 36111839)
1. A Delay in Adjuvant Therapy Is Associated With Worse Prognosis Only in Patients With Transitional Circulating Tumor Cells After Resection of Pancreatic Ductal Adenocarcinoma.
Javed AA; Floortje van Oosten A; Habib JR; Hasanain A; Kinny-Köster B; Gemenetzis G; Groot VP; Ding D; Cameron JL; Lafaro KJ; Burns WR; Burkhart RA; Yu J; He J; Wolfgang CL
Ann Surg; 2023 Jun; 277(6):866-872. PubMed ID: 36111839
[TBL] [Abstract][Full Text] [Related]
2. Persistent Circulating Tumor Cells at 1 Year After Oncologic Resection Predict Late Recurrence in Pancreatic Cancer.
Javed AA; Ding D; Hasanain A; van Oosten F; Yu J; Cameron JL; Burkhart RA; Zheng L; He J; Wolfgang CL
Ann Surg; 2023 Jun; 277(6):859-865. PubMed ID: 36111892
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status: Results of the Prospective CLUSTER Study.
Gemenetzis G; Groot VP; Yu J; Ding D; Teinor JA; Javed AA; Wood LD; Burkhart RA; Cameron JL; Makary MA; Weiss MJ; He J; Wolfgang CL
Ann Surg; 2018 Sep; 268(3):408-420. PubMed ID: 30080739
[TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer.
Court CM; Ankeny JS; Sho S; Winograd P; Hou S; Song M; Wainberg ZA; Girgis MD; Graeber TG; Agopian VG; Tseng HR; Tomlinson JS
Ann Surg Oncol; 2018 Apr; 25(4):1000-1008. PubMed ID: 29442211
[TBL] [Abstract][Full Text] [Related]
5. Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma.
White MG; Lee A; Vicente D; Hall C; Kim MP; Katz MHG; Lee JE; Ikoma N; Lucci A; Tzeng CD
Ann Surg Oncol; 2021 Aug; 28(8):4615-4622. PubMed ID: 33415562
[TBL] [Abstract][Full Text] [Related]
6. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
[TBL] [Abstract][Full Text] [Related]
7. Major Postoperative Complications Limit Adjuvant Therapy Administration in Patients Undergoing Pancreatoduodenectomy for Distal Cholangiocarcinoma or Pancreatic Ductal Adenocarcinoma.
Macfie R; Berger Y; Liu H; Li T; Imtiaz S; Ang C; Sarpel U; Hiotis S; Labow D; Golas B; Cohen NA
Ann Surg Oncol; 2023 Aug; 30(8):5027-5034. PubMed ID: 37210446
[TBL] [Abstract][Full Text] [Related]
8. Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma.
Poruk KE; Blackford AL; Weiss MJ; Cameron JL; He J; Goggins M; Rasheed ZA; Wolfgang CL; Wood LD
Clin Cancer Res; 2017 Jun; 23(11):2681-2690. PubMed ID: 27789528
[No Abstract] [Full Text] [Related]
9. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma.
Poruk KE; Valero V; Saunders T; Blackford AL; Griffin JF; Poling J; Hruban RH; Anders RA; Herman J; Zheng L; Rasheed ZA; Laheru DA; Ahuja N; Weiss MJ; Cameron JL; Goggins M; Iacobuzio-Donahue CA; Wood LD; Wolfgang CL
Ann Surg; 2016 Dec; 264(6):1073-1081. PubMed ID: 26756760
[TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma.
Vicente D; Lee AJ; Hall CS; Lucci A; Lee JE; Kim MP; Katz MHG; Hurd MW; Maitra A; Rhim Md AD; Tzeng CD
J Surg Res; 2019 Nov; 243():90-99. PubMed ID: 31170555
[TBL] [Abstract][Full Text] [Related]
11. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
12. CTC phenotyping for a preoperative assessment of tumor metastasis and overall survival of pancreatic ductal adenocarcinoma patients.
Sun Y; Wu G; Cheng KS; Chen A; Neoh KH; Chen S; Tang Z; Lee PF; Dai M; Han RPS
EBioMedicine; 2019 Aug; 46():133-149. PubMed ID: 31375425
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.
Hussung S; Akhoundova D; Hipp J; Follo M; Klar RFU; Philipp U; Scherer F; von Bubnoff N; Duyster J; Boerries M; Wittel U; Fritsch RM
BMC Cancer; 2021 Jan; 21(1):49. PubMed ID: 33430810
[TBL] [Abstract][Full Text] [Related]
14. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of circulating tumor cells in pancreatic ductal adenocarcinoma: potential diagnostic and prognostic significance in clinical practice.
Zhao X; Ma Y; Dong X; Zhang Z; Tian X; Zhao X; Yang Y
Hepatobiliary Surg Nutr; 2021 Dec; 10(6):796-810. PubMed ID: 35004946
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma.
Park Y; Jun HR; Choi HW; Hwang DW; Lee JH; Song KB; Lee W; Kwon J; Ha SH; Jun E; Kim SC
Sci Rep; 2021 Jan; 11(1):1644. PubMed ID: 33462311
[TBL] [Abstract][Full Text] [Related]
17. Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients.
Papadakis GZ; Mavroudis D; Georgoulias V; Souglakos J; Alegakis AK; Samonis G; Bagci U; Makrigiannakis A; Zoras O
Growth Horm IGF Res; 2017 Apr; 33():28-34. PubMed ID: 28258988
[TBL] [Abstract][Full Text] [Related]
18. Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma.
Chapin WJ; Till JE; Hwang WT; Eads JR; Karasic TB; O'Dwyer PJ; Schneider CJ; Teitelbaum UR; Romeo J; Black TA; Christensen TE; Redlinger Tabery C; Anderson A; Slade M; LaRiviere M; Yee SS; Reiss KA; O'Hara MH; Carpenter EL
JCO Precis Oncol; 2022 Jul; 6():e2200060. PubMed ID: 35939771
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection.
Murakawa M; Kawahara S; Takahashi D; Kamioka Y; Yamamoto N; Kobayashi S; Ueno M; Morimoto M; Sawazaki S; Tamagawa H; Ohshima T; Yukawa N; Rino Y; Morinaga S
World J Surg Oncol; 2023 Aug; 21(1):263. PubMed ID: 37620940
[TBL] [Abstract][Full Text] [Related]
20. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
